A Dose-escalating Study to Evaluate the Immunogenicity and Safety of Rotavin-M1 Vaccine in Healthy Infants

Diarrhea Clinical Trial

Official title:

A Phase II, Randomized, Double-blind, Vaccine-controlled Dose-escalating Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotavin-M1) in Healthy Infants in Vietnam

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01377571
• Other study ID #: Rotavin02
• Secondary ID: KC.10.33/06-10
• Status: Completed
• Phase: Phase 2
• First received: May 19, 2011
• Last updated: June 30, 2016
• Start date: October 2009
• Est. completion date: April 2010

Study information

• Verified date: June 2016
• Source: National Institute of Hygiene and Epidemiology, Vietnam
• Contact: n/a
• Is FDA regulated: No
• Health authority: Vietnam: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and immunogenicity of Rotavin-M1 produced by the Center for Research and Production of Vaccines and Biologicals (POLYVAC) in infants in Vietnam. In addition, we evaluate different dosages and schedules to determine the best regimen to test in a clinical trial.

Description:

Rotavirus (RV) is the most important cause of acute gastroenteritis in children worldwide. In Vietnam rotavirus causes an estimated 122,000-140,000 hospitalizations and 2900-5400 deaths per year among children under 5 years of age (1). Over the past 13 years, sentinel hospital surveillance identified rotavirus in 44%-62% of children admitted for the treatment of acute diarrhea in Vietnam (2-4). Such a high burden of disease justified accelerated development of a new and locally manufactured vaccine against rotavirus in Vietnam. It is estimated that if a vaccine was introduced in the current childhood immunization schedule, it could reduce severe rotavirus disease by about 60% or more given current vaccine efficacies and coverage (5).

The Government of Vietnam has pursued a policy to encourage local vaccine production so the country could be self-reliant with affordable vaccines for its population (6). Over the past decades, several locally produced vaccines for poliomyelitis, cholera, Japanese encephalitis, and Diphtheria-Pertussis-Tetanus have contributed to the reduction in the prevalence of these diseases and to the eradication of polio over the past decade. While two commercial rotavirus vaccines, RotarixTM (GSK, Belgium) and RotaTeq® (Merck), have both been tested in Vietnam, neither is currently available at an affordable cost for the national program. Therefore, the candidate vaccine, Rotavin-M1, was developed in order to fill this need for a more affordable vaccine for Vietnamese children (6). This vaccine is similar to RotarixTM, and was developed by selecting a common G1P[8] strain and attenuating it through serial passages and plaque purification in qualified Vero cells under GLP conditions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: April 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 6 Weeks to 12 Weeks

Eligibility

Inclusion Criteria:

• At dose 1

1. A healthy male or female, 6 to 12 weeks of age (42 days to 84 days of age).

2. Full term gestation (>=37 weeks).

3. Birth weight of the subject should be >=2.5 kg.

4. Healthy subjects as established by medical history and clinical examination before entering into the study.

5. Did not use any dose of Rota virus vaccine.

6. Written informed consent obtained from the parent or guardian of the subject.

• At dose 2

1. Received dose 1.

2. Oral informed consent obtained from the parent or guardian of the subject for continuing participate the study.

• At dose 3

1. Received both dose 1 and dose 2.

2. Oral informed consent obtained from the parent or guardian of the subject for continuing participate the study.

Exclusion Criteria:

• At dose 1

1. Has a chronic disease (cardiovascular, liver, kidney disease).

2. Acute disease at the time of enrolment.

3. Administering corticosteroids (> 1mg/kg/day).

4. Received any immunosuppressive therapy within 4 week before vaccination (Administration of immunoglobulins and/or any blood product or corticosteroids for >2 weeks).

5. Immunosuppressive or immunodeficient condition.

6. Family has immunosuppressive or immunodeficient condition medical history.

7. History of high fever convulsion.

8. Allergic or reaction with any component of vaccine, includes anaphylactic shock with any antibiotic.

9. Preterm of gestation delivery (gestation period < 37 weeks).

10. Low birth weight (<2.5 kg).

11. Fever (axillary temperature >38oC) within 3 days before or on the day of vaccination.

12. Malnutrition.

13. Has any type of blood disorder, leukemia, or malignant tumor which can affect the bone marrow or lymph system.

14. Use of any investigational or non-registered product (unlicensed drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.

• At dose 2

1. Acute disease at the time of 2nd dose.

2. Administering corticosteroids (> 1mg/kg/day).

3. Received any immunosuppressive therapy within 4 week before vaccination (Administration of immunoglobulins and/or any blood product or corticosteroids for >2 weeks).

4. History of allergic disease or reactions likely to be exacerbated by any component of the study vaccine.

5. Fever (axillary temperature >38oC) within 3 days before or on the day of vaccination.

6. Has any type of blood disorder, leukemia, or malignant tumor which can affect the bone marrow or lymph system.

7. Use of any investigational or non-registered product (unlicensed drug or vaccine) other than the study vaccine during the study period.

• At dose 3

1. Acute disease at the time of 3rd dose.

2. Administering corticosteroids (> 1mg/kg/day).

3. Received any immunosuppressive therapy within 4 week before vaccination (Administration of immunoglobulins and/or any blood product or corticosteroids for >2 weeks).

4. History of allergic disease or reactions likely to be exacerbated by any component of the study vaccine.

5. Fever (axillary temperature >38oC) within 3 days before or on the day of vaccination.

6. Has any type of blood disorder, leukemia, or malignant tumor which can affect the bone marrow or lymph system.

7. Use of any investigational or non-registered product (unlicensed drug or vaccine) other than the study vaccine during the study period.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Related Conditions & MeSH terms

• Diarrhea
• Fever
• Irritability
• Nausea
• Vomit

Intervention

Biological:
• Rotarix
2 doses of Rotarix vaccine, 106.5CID/dose, 1-month interval between doses

Locations

Country	Name	City	State
Vietnam	Preventive Medicine center	Thanh Son	Phu Tho

Sponsors (2)

Lead Sponsor	Collaborator
National Institute of Hygiene and Epidemiology, Vietnam	Center for Research and Production of Vaccines and Biologicals, Vietnam

Country where clinical trial is conducted

Vietnam, 

References & Publications (6)

Anh DD, Thiem VD, Fischer TK, Canh DG, Minh TT, Tho le H, Van Man N, Luan le T, Kilgore P, von Seidlein L, Glass RI. The burden of rotavirus diarrhea in Khanh Hoa Province, Vietnam: baseline assessment for a rotavirus vaccine trial. Pediatr Infect Dis J. 2006 Jan;25(1):37-40. — View Citation

Kim SY, Goldie SJ, Salomon JA. Cost-effectiveness of Rotavirus vaccination in Vietnam. BMC Public Health. 2009 Jan 21;9:29. doi: 10.1186/1471-2458-9-29. — View Citation

Luan le T, Trang NV, Phuong NM, Nguyen HT, Ngo HT, Nguyen HT, Tran HB, Dang HN, Dang AD, Gentsch JR, Wang Y, Esona MD, Glass RI, Steele AD, Kilgore PE, Nguyen MV, Jiang B, Nguyen HD. Development and characterization of candidate rotavirus vaccine strains derived from children with diarrhoea in Vietnam. Vaccine. 2009 Nov 20;27 Suppl 5:F130-8. doi: 10.1016/j.vaccine.2009.08.086. — View Citation

Ngo TC, Nguyen BM, Dang DA, Nguyen HT, Nguyen TT, Tran VN, Vu TT, Ogino M, Alam MM, Nakagomi T, Nakagomi O, Yamashiro T. Molecular epidemiology of rotavirus diarrhoea among children in Haiphong, Vietnam: the emergence of G3 rotavirus. Vaccine. 2009 Nov 20;27 Suppl 5:F75-80. doi: 10.1016/j.vaccine.2009.08.074. — View Citation

Nguyen TA, Yagyu F, Okame M, Phan TG, Trinh QD, Yan H, Hoang KT, Cao AT, Le Hoang P, Okitsu S, Ushijima H. Diversity of viruses associated with acute gastroenteritis in children hospitalized with diarrhea in Ho Chi Minh City, Vietnam. J Med Virol. 2007 May;79(5):582-90. — View Citation

Van Man N, Luan le T, Trach DD, Thanh NT, Van Tu P, Long NT, Anh DD, Fischer TK, Ivanoff B, Gentsch JR, Glass RI; Vietnam Rotavirus Surveillance Network. Epidemiological profile and burden of rotavirus diarrhea in Vietnam: 5 years of sentinel hospital surveillance, 1998-2003. J Infect Dis. 2005 Sep 1;192 Suppl 1:S127-32. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess immunogenicity of a new rotavirus vaccine Rotavin-M1 in terms of anti-rotavirus IgA antibody seroconversion 1 month after complete the vaccination schedule	To assess immunogenicity of Rotavin-M1 of 2 titers (10e6.0 and 10e6.3FFU/dose) and 2 schedules (3 doses and 1-month interval between vs 2 doses and 2-month interval between doses), compared with 2 doses GSK's lyophilized Rotarix (10e6.5 CID50/dose).	up to 7 months	Yes
Secondary	To assess immunogenicity of Rotavin-M1 vaccine versus GSK Biologicals' HRV vaccine in terms of anti-rotavirus IgA antibody seroconversion at Month 2 in the group receiving the vaccines.	To assess immunogenicity of Rotavin-M1 vaccine (of different dosages and schedules) versus GSK Biologicals' HRV vaccine in terms of anti-rotavirus IgA antibody seroconversion at Month 2 in the group receiving the vaccines.	up to 7 months	Yes
Secondary	To assess immunogenicity of Rotavin-M1 vaccine versus GSK Biologicals' HRV vaccine in terms of anti-rotavirus IgA antibody GMT at Month 2 in the group receiving the vaccines.	To assess immunogenicity of Rotavin-M1 vaccine (of different dosages and schedules) versus GSK Biologicals' HRV vaccine in terms of anti-rotavirus IgA antibody GMT at Month 2 in the group receiving the vaccines.	up to 7 months	Yes
Secondary	To assess immunogenicity of Rotavin-M1 vaccine versus GSK Biologicals' HRV vaccine in terms of anti-rotavirus IgA antibody GMT at Month 3 in the group receiving the vaccines.	To assess immunogenicity of Rotavin-M1 vaccine (of different dosages and schedules) versus GSK Biologicals' HRV vaccine in terms of anti-rotavirus IgA antibody GMT at Month 3 in the group receiving the vaccines.	up to 7 months	Yes
Secondary	To assess the safety and reactogenicity of each dose of Rotavin-M1 versus GSK's biologicals Rotarix	To assess immediate reactions (30minutes) after administration of each dose To assess adverse events 30 days after each dose To assess change in blood cell counts (red blood cells, white blood cells, platelets), blood urea nitrogen concentration, transaminase concentration (ALT, AST)	up to 7 months	Yes
Secondary	To assess the presence of rotavirus (RV) in GE stools collected after administration of first dose of the study vaccine up to 1 month after the last dose.	To assess the presence of rotavirus (RV) in GE stools collected after administration of the first dose of the study vaccine up to 1 month after the last dose.	up to 7 months	Yes
Secondary	To assess the shedding of rotavirus (RV) in stools collected daily for 7 days after administration of each dose of the study vaccine.	To assess the shedding of rotavirus (RV) in stools collected daily for 7 days after administration of each dose of the study vaccine	up to 7 months	Yes
Secondary	To compare the RV antibody titers 1 year after the first doses between one Rotavin-M1 group and Rotarix	To assess the RV antibody titers 1 year after the 1st dose between Rotavin-M1 group (106.3FFU/dose, 2 doses, 2-month interval) and Rotarix group (106.0CID/dose, 2 doses, 1-month interval between doses).	up to 15 months	No